TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38573915

Group type: EXPERIMENTAL
Intervention: RIF+AMX/CLV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RIF+CLA+AMX/CLV
Number of subjects: 0

Group type: COMPARATOR
Intervention: RIF+CLA
Number of subjects: 0
Study: 38573925

Group type: EXPERIMENTAL
Intervention: Hydrashift isatuximab assay
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard IFE
Number of subjects: 141
Study: 38574044

Group type: EXPERIMENTAL
Intervention: HIPEC with doxorubicin
Number of subjects: 6
Study: 38574312

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m) and Gemcitabine with Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 57
Study: 38574330

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38574351

Group type: EXPERIMENTAL
Intervention: HEMOPHAR e-learning program
Number of subjects: 502
Study: 38574400

Group type: EXPERIMENTAL
Intervention: Frontal white matter hyperintensities (WMH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occipital white matter hyperintensities (WMH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amyloid beta (Aβ) pathology
Number of subjects: 0
Study: 38574739

Group type: EXPERIMENTAL
Intervention: ZF2202-A booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: BA.2.86
Number of subjects: 0

Group type: COMPARATOR
Intervention: JN.1
Number of subjects: 0

Group type: COMPARATOR
Intervention: EG.5
Number of subjects: 0
Study: 38574757

Group type: EXPERIMENTAL
Intervention: Ticagrelor-based dual antiplatelet therapy (DAPT) for 1 month
Number of subjects: 2617

Group type: EXPERIMENTAL
Intervention: Continued ticagrelor from 1 to 12 months
Number of subjects: 2617

Group type: EXPERIMENTAL
Intervention: De-escalation to clopidogrel from 1 to 12 months
Number of subjects: 2617

Group type: EXPERIMENTAL
Intervention: Switching from ticagrelor to clopidogrel after 1 month
Number of subjects: 2617
Study: 38574853

Group type: EXPERIMENTAL
Intervention: Interventional psychiatric treatments (INTs) including electroconvulsive therapy, transcranial magnetic stimulation, and esketamine
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Interventional psychiatric treatments (INTs)
Number of subjects: 493

Group type: COMPARATOR
Intervention: No INT
Number of subjects: 493
Study: 38574873

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
Number of subjects: 208
Study: 38574876

Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PCC)
Number of subjects: 32
Study: 38574978

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (n = 10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls (n = 7)
Number of subjects: 32
Study: 38575049

Group type: EXPERIMENTAL
Intervention: CHESS system intervention group
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 1600
Study: 38575104

Group type: EXPERIMENTAL
Intervention: Perioperative pain neuroscience education (PPNE)
Number of subjects: 120
Study: 38575409

Group type: EXPERIMENTAL
Intervention: Immune-based combinations (IO)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 200
Study: 38575433

Group type: EXPERIMENTAL
Intervention: IndoVac
Number of subjects: 4050

Group type: COMPARATOR
Intervention: Covovax
Number of subjects: 4050
Study: 38575449

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6006

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 6006
Study: 38575674

Group type: EXPERIMENTAL
Intervention: Baecke questionnaire total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baecke questionnaire without Sport Index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leisure-time MET-Index
Number of subjects: 0
Study: 38575729

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52
Number of subjects: 55
Study: 38575731

Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg once daily
Number of subjects: 106
Study: 38575854

Group type: EXPERIMENTAL
Intervention: Rapamycin (7 mg weekly for six months)
Number of subjects: 15
Study: 38575887

Group type: EXPERIMENTAL
Intervention: Patient education intervention (educational waiting room posters and flyers)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 26
Study: 38575888

Group type: EXPERIMENTAL
Intervention: Mindfulness-based resilience training (MBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (stress management education [SME])
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study: 38575929

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention consisting of prescriber education via academic detailing, standardized patient post-extraction instructions, and blister packs of acetaminophen and ibuprofen.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention.
Number of subjects: 33
Study: 38575938

Group type: EXPERIMENTAL
Intervention: BETTER HEALTH intervention delivered by public health nurses
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BETTER HEALTH intervention
Number of subjects: 38
Study: 38575945

Group type: EXPERIMENTAL
Intervention: JoyPop app (4 weeks, at least twice daily usage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (monitoring)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JoyPop app
Number of subjects: 0
Study: 38575952

Group type: EXPERIMENTAL
Intervention: Orchestra in Class (OC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Visual Arts (VA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 150
Study: 38576007

Group type: EXPERIMENTAL
Intervention: 60% initial oxygen concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower oxygen concentration (not specified)
Number of subjects: 0
Study: 38576033

Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38576046

Group type: EXPERIMENTAL
Intervention: Active robot-assisted resistance training
Number of subjects: 488

Group type: COMPARATOR
Intervention: Passive robot-assisted sham training
Number of subjects: 488
Study: 38576165

Group type: EXPERIMENTAL
Intervention: Conservative Approach to Fluid Therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Liberal Approach to Fluid Therapy
Number of subjects: 100
Study: 38576178

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: BRV 200 mg/day
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 38577337

Group type: EXPERIMENTAL
Intervention: TYRP1-TCB (RO7293583) administered in escalating doses (0.045 to 0.4 mg)
Number of subjects: 20
Study: 38577523

Group type: EXPERIMENTAL
Intervention: Flavonoid intervention for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 38577571

Group type: EXPERIMENTAL
Intervention: Micronized natural progesterone protocol
Number of subjects: 150

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 150
Study: 38577574

Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg/28 days intramuscularly for acromegaly or pasireotide 600 μg subcutaneously twice daily for Cushing's disease.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Incretin-based therapy or insulin (for those requiring additional/alternative antihyperglycemic medication).
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Metformin (for those who did not need antihyperglycemic medication).
Number of subjects: 249
Study: 38577701

Group type: EXPERIMENTAL
Intervention: MRSA surgical site infection (SSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Country-specific incidence rates of MRSA SSI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Centres with established ABS and ID consultation programmes
Number of subjects: 0
Study: 38577931

Group type: EXPERIMENTAL
Intervention: ACURATE neo2
Number of subjects: 296

Group type: COMPARATOR
Intervention: ACURATE neo
Number of subjects: 296
Study: 38578158

Group type: EXPERIMENTAL
Intervention: High postoperative lactate (≥ 4 mmol/L)
Number of subjects: 132
Study: 38578289

Group type: EXPERIMENTAL
Intervention: Patient Dignity Inventory (PDI-CZ)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Cognitive function, self-sufficiency, vision, and hearing assessments
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Social involvement items
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Predictors of self-sufficiency and pain
Number of subjects: 258
Study: 38578352

Group type: EXPERIMENTAL
Intervention: B-type sutured ileostomy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Traditional ileostomy (Control)
Number of subjects: 124
Study: 38578394

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) at a dosage of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Total antibody (tAB)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Free SN-38
Number of subjects: 529
Study: 38578534

Group type: EXPERIMENTAL
Intervention: Younger participants (≤40 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher education, being male, and earning $20,000-$39,999
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somali immigrants who are younger, more formally educated, male, and/or earn $20,000-$39,000
Number of subjects: 0
Study: 38578537

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 143
Study: 38578640

Group type: EXPERIMENTAL
Intervention: Hypofractionated RNI (40.05 Gy/15 fractions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated RNI (50 Gy/25 fractions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall treatment (PreMRT and RNI followed by mastectomy and IMBR)
Number of subjects: 50
Study: 38578666

Group type: EXPERIMENTAL
Intervention: eCDSS plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 38578667

Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - 4 sessions of VR-based self-conversations with ConVRself after intensive motivational interviewing training.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - 4 VR-based sessions led by a virtual counselor with a prerecorded discourse, undergoing embodiment technique.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control Group (CG) - Treatment as usual from the obesity unit.
Number of subjects: 68
Study: 38578673

Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption (4-session MI intervention)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption and Environmental Risk (EMI with MI and real-time messaging)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Smartphone-based alcohol monitoring-only control group
Number of subjects: 405
Study: 38578675

Group type: EXPERIMENTAL
Intervention: TeNDER technological tool for health and self-care
Number of subjects: 38
Study: 38578686

Group type: EXPERIMENTAL
Intervention: Self-guided lifestyle intervention (12-week duration, including 1 virtual group session, digital tools, access to self-paced web- and mobile-based content, and 12 weekly health risk text messages)
Number of subjects: 14
Study: 38578690

Group type: EXPERIMENTAL
Intervention: MOBICPR intervention group (MOBICPR-IG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait-list control group (WL-CG)
Number of subjects: 43
Study: 38578720

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 177
Study: 38579294

Group type: EXPERIMENTAL
Intervention: Lp(a) levels in patients with LAA stroke
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Log10 Lp(a) levels
Number of subjects: 743

Group type: COMPARATOR
Intervention: Lp(a) levels in patients with diabetes
Number of subjects: 743
Study: 38579297

Group type: EXPERIMENTAL
Intervention: 60 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15
Study: 38579300

Group type: EXPERIMENTAL
Intervention: In-hospital intervention (evaluation of inhalation technique and PIF, provision of a written guide, therapeutic education)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: In-hospital intervention
Number of subjects: 93
Study: 38579309

Group type: EXPERIMENTAL
Intervention: Usual oncology care plus the palliative care intervention (SENS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 58
Study: 38579315

Group type: EXPERIMENTAL
Intervention: NSAID-based pain control (oral acetaminophen and intravenous ketorolac)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Opioid-based pain control
Number of subjects: 96
Study: 38579579

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 38579696

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38579729

Group type: EXPERIMENTAL
Intervention: Inflammation score based on identified inflammatory proteins
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: SERPINA9, TACI, and TARC
Number of subjects: 109
Study: 38579940

Group type: EXPERIMENTAL
Intervention: DOAC score
Number of subjects: 14672

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 14672
Study: 38580007

Group type: EXPERIMENTAL
Intervention: High serum uric acid levels
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Low serum uric acid levels
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Serum uric acid levels (dose-response analysis)
Number of subjects: 1014
Study: 38580133

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for absolute indication EGC
Number of subjects: 149

Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for relative indication EGC
Number of subjects: 149
Study: 38580298

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 272

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 272
Study: 38580333

Group type: EXPERIMENTAL
Intervention: ImmunoPET imaging with PD-L1-targeted tracers
Number of subjects: 0
Study: 38580339

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided high-intensity focused ultrasound (HIFU)
Number of subjects: 30
Study: 38580350

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Any treatment (conventional or biological antirheumatic treatment)
Number of subjects: 793
Study: 38580355

Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists (clonidine and dexmedetomidine)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study: 38580363

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition with arginine-enhanced diets
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study: 38580373

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (pharmacological nutritional hypercaloric products)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-appropriate and gender-appropriate nutritional intake
Number of subjects: 0
Study: 38580386

Group type: EXPERIMENTAL
Intervention: 15 mg vedo-800CW
Number of subjects: 43

Group type: COMPARATOR
Intervention: 15 mg vedo-800CW after unlabelled vedolizumab
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4.5 mg vedo-800CW
Number of subjects: 43
Study: 38580424

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4017

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study: 38580444

Group type: EXPERIMENTAL
Intervention: Monthly emailed behavioural 'nudge' messages encouraging compliance with social norms and clinical guidelines around prescribing.
Number of subjects: 36
Study: 38580558

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control (non-anticoagulated)
Number of subjects: 283
Study: 38580913

Group type: EXPERIMENTAL
Intervention: Home-based motor-cognitive eHealth exercise intervention using the ExorLive® application for 10 weeks
Number of subjects: 15
Study: 38580946

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study: 38580992

Group type: EXPERIMENTAL
Intervention: Dialogical Family Guidance (DFG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (DFG after a three-month waiting period)
Number of subjects: 50
Study: 38581030

Group type: EXPERIMENTAL
Intervention: Volatile sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study: 38581046

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise
Number of subjects: 35

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 35
Study: 38581075

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) and procalcitonin (PCT)
Number of subjects: 194
Study: 38581254

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening (PSA test, 4-kallikrein panel, MRI)
Number of subjects: 60745

Group type: COMPARATOR
Intervention: Not invited to undergo screening
Number of subjects: 60745
Study: 38581363

Group type: EXPERIMENTAL
Intervention: Work schedule with abated quick returns (i.e. > 11 hours between two shifts)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Control group (shift schedule maintaining the usual number of quick returns)
Number of subjects: 1314
Study: 38581389

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 6522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study: 38581449

Group type: EXPERIMENTAL
Intervention: Type 1 (slow-twitch) fibres
Number of subjects: 18

Group type: COMPARATOR
Intervention: Type 2 (fast-twitch) fibres
Number of subjects: 18
Study: 38581469

Group type: EXPERIMENTAL
Intervention: PRRT with [177Lu]Lu-DOTATATE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular imaging with different radiopharmaceuticals (e.g., SST and FDG)
Number of subjects: 0
Study: 38581480

Group type: EXPERIMENTAL
Intervention: Entresto (sacubitril)
Number of subjects: 0
Study: 38581534

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eribulin and AIs (combined treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Number of subjects: 0
Study: 38581600

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Training for rheumatology groups
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Barriers to POCUS use
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: POCUS infrastructure
Number of subjects: 95
Study: 38581615

Group type: EXPERIMENTAL
Intervention: GMB120 (120 mg)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: GMB240 (240 mg)
Number of subjects: 461

Group type: COMPARATOR
Intervention: PBO (Placebo)
Number of subjects: 461
Study: 38581616

Group type: EXPERIMENTAL
Intervention: Donanemab (700 mg for three doses, then 1400 mg/dose, intravenous every 4 weeks for 72 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 38581739

Group type: EXPERIMENTAL
Intervention: Psilocybin pulse (10 mg/70 kg, 3 doses, 5 days apart)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 10
Study: 38581814

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 542
Study: 38581842

Group type: EXPERIMENTAL
Intervention: Sitagliptin with basal-plus (BP) insulin regimen
Number of subjects: 76

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 76
Study: 38581926

Group type: EXPERIMENTAL
Intervention: Variable tidal volume (6 ml/kg PBW ± 33% at 5-min intervals)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fixed tidal volume (6 ml/kg PBW)
Number of subjects: 140
Study: 38581958

Group type: EXPERIMENTAL
Intervention: New patient-centred care pathway
Number of subjects: 720

Group type: COMPARATOR
Intervention: Usual oncologic care
Number of subjects: 720
Study: 38582028

Group type: EXPERIMENTAL
Intervention: Overground locomotor training
Number of subjects: 12
Study: 38582092

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m²) in group A
Number of subjects: 356

Group type: COMPARATOR
Intervention: Chemotherapy-free treatment with trastuzumab and pertuzumab in group B
Number of subjects: 356
Study: 38582271

Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg twice a day for 3 days, then 20 mg once a day for 28 days)
Number of subjects: 194

Group type: COMPARATOR
Intervention: High-dose PPI (pantoprazole intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Vonoprazan
Number of subjects: 194